Texas is currently home to 4897 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
Recruiting
This is a phase 1, multicenter, randomized, double-blind trial of two influenza A/H5 mRNA-based vaccines on healthy adult participants, 18-49 years of age. Stage 1 will serve as the open-label, dose finding stage. The first 10 participants will receive 12.5 mcg of H5 AC-Anhui RNA vaccine (Group 1), and the second 10 participants will receive 25 mcg of H5 AC-Anhui RNA vaccine (Group 2). After Protocol Safety Review Team (PSRT) review of reactogenicity and safety data through Day 8 for both Groups... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
07/10/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Avian Influenza
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Recruiting
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/10/2025
Locations: Aclaris Study Site, San Antonio, Texas
Conditions: Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Recruiting
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from partici... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Urology San Antonio, San Antonio, Texas
Conditions: Metastatic Hormone-sensitive Prostate Cancer
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/10/2025
Locations: Investigative Site US032, Dallas, Texas
Conditions: Hidradenitis Suppurativa
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Recruiting
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas, Texas
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
07/10/2025
Locations: Dell Medical School, University of Texas at Austin, Austin, Texas
Conditions: Major Depressive Disorder
SPYRAL GEMINI Pilot Study
Recruiting
The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/10/2025
Locations: Baylor Heart & Vascular Hospital, Dallas, Texas
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
Recruiting
The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/10/2025
Locations: Pinnacle Clinical Research - Austin, Austin, Texas
Conditions: MASH
Fertilo In Vitro Research Study and Trial
Recruiting
The goal of this clinical trial is to evaluate the safety and efficacy of using Fertilo for In vitro maturation (IVM) in participants 18-35 years of age. The main question it aims to answer is whether the use of Fertilo is superior to using Medicult IVM for In vitro maturation. Researchers will compare the number of ongoing pregnancies at 12 weeks gestation for participants in each arm. * Arm 1 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cult... Read More
Gender:
FEMALE
Ages:
Between 18 years and 35 years
Trial Updated:
07/10/2025
Locations: Shady Grove Houston, Webster, Texas
Conditions: In Vitro Maturation of Oocytes
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Recruiting
This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/refractory AML, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Recruiting
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-00... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Studies in Dermatology LLC, Cypress, Texas
Conditions: Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Recruiting
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/10/2025
Locations: Perceptive Pharma Research /ID# 267836, Richmond, Texas
Conditions: Generalized Anxiety Disorder (GAD)